Renesto P, Si-Tahar M, Moniatte M, Balloy V, Van Dorsselaer A, Pidard D, Chignard M
Unité de Pharmacologie Cellulaire, Institut Pasteur, Paris, France.
Blood. 1997 Mar 15;89(6):1944-53.
The aim of this study was to investigate the inhibitory effects of human leukocyte elastase (HLE), cathepsin G (Cat G), and proteinase 3 (PR3) on the activation of endothelial cells (ECs) and platelets by thrombin and to elucidate the underlying mechanisms. Although preincubation of ECs with HLE or Cat G prevented cytosolic calcium mobilization and prostacyclin synthesis induced by thrombin, these cell responses were not affected when triggered by TRAP42-55, a synthetic peptide corresponding to the sequence of the tethered ligand (Ser42-Phe55) unmasked by thrombin on cleavage of its receptor. Using IIaR-A, a monoclonal antibody directed against the sequence encompassing this cleavage site, flow cytometry analysis showed that the surface expression of this epitope was abolished after incubation of ECs with HLE or Cat G. Further experiments conducted with platelets indicated that not only HLE and Cat G but also PR3 inhibited cell activation induced by thrombin, although they were again ineffective when TRAP42-55 was the agonist. Similar to that for ECs, the epitope for IIaR-A disappeared on treatment of platelets with either proteinase. These results suggested that the neutrophil enzymes proteolyzed the thrombin receptor downstream of the thrombin cleavage site (Arg41-Ser42) but left intact the TRAP42-55 binding site (Gln83-Ser93) within the extracellular aminoterminal domain. The capacity of these proteinases to cleave five overlapping synthetic peptides mapping the portion of the receptor from Asn35 to Pro85 was then investigated. Mass spectrometry studies showed several distinct cleavage sites, i.e., two for HLE (Val(72)-Ser73 and Ile74-Asn75), three for Cat G (Arg41-Ser42, Phe55-Trp56 and Tyr69-Arg70), and one for PR3 (Val(72)-Ser73). We conclude that this singular susceptibility of the thrombin receptor to proteolysis accounts for the ability of neutrophil proteinases to inhibit cell responses to thrombin.
本研究的目的是探讨人白细胞弹性蛋白酶(HLE)、组织蛋白酶G(Cat G)和蛋白酶3(PR3)对凝血酶激活内皮细胞(ECs)和血小板的抑制作用,并阐明其潜在机制。虽然用HLE或Cat G预孵育ECs可防止凝血酶诱导的胞质钙动员和前列环素合成,但当由TRAP42 - 55触发时,这些细胞反应不受影响,TRAP42 - 55是一种合成肽,对应于凝血酶切割其受体时暴露的拴系配体序列(Ser42 - Phe55)。使用IIaR - A,一种针对包含该切割位点序列的单克隆抗体,流式细胞术分析表明,在用HLE或Cat G孵育ECs后,该表位的表面表达消失。对血小板进行的进一步实验表明,不仅HLE和Cat G,而且PR3也抑制凝血酶诱导的细胞激活,尽管当TRAP42 - 55作为激动剂时它们再次无效。与ECs类似,用任何一种蛋白酶处理血小板后,IIaR - A的表位消失。这些结果表明,中性粒细胞酶在凝血酶切割位点(Arg41 - Ser42)下游对凝血酶受体进行蛋白水解,但细胞外氨基末端结构域内的TRAP42 - 55结合位点(Gln83 - Ser93)保持完整。然后研究了这些蛋白酶切割五个重叠合成肽的能力,这些合成肽描绘了受体从Asn35到Pro85的部分。质谱研究显示了几个不同的切割位点,即HLE的两个(Val(72)-Ser73和Ile74 - Asn75)、Cat G的三个(Arg41 - Ser42、Phe55 - Trp56和Tyr69 - Arg70)以及PR3的一个(Val(72)-Ser73)。我们得出结论,凝血酶受体对蛋白水解的这种独特敏感性解释了中性粒细胞蛋白酶抑制细胞对凝血酶反应的能力。